Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Aldeyra Therapeutics
(NASDAQ:ALDX)
Intraday
$3.97
0.10
[2.58%]
After-Hours
$3.97
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$3.97
0.10
[2.58%]
At close: Apr 17
$3.97
0
[0.00%]
After Hours: 4:00PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Aldeyra Therapeutics Stock (NASDAQ:ALDX)
Aldeyra Therapeutics Stock (NASDAQ: ALDX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, April 04, 2024
Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
Avi Kapoor
-
Apr 4, 2024, 6:23AM
Wednesday, April 03, 2024
Aldeyra Therapeutics shares are trading higher after Oppenheimer upgraded the stock from Perform to Outperform and announced a $10 price target.
Benzinga Newsdesk
-
Apr 3, 2024, 12:02PM
Oppenheimer Upgrades Aldeyra Therapeutics to Outperform, Announces $10 Price Target
Benzinga Newsdesk
-
Apr 3, 2024, 9:58AM
Tuesday, April 02, 2024
HC Wainwright & Co. Reinstates Buy on Aldeyra Therapeutics, Announces $10 Price Target
Benzinga Newsdesk
-
Apr 2, 2024, 8:43AM
Thursday, March 28, 2024
Aldeyra Therapeutics shares are trading higher. The company announced the clinical development plan intended to enable resubmission of a New Drug Application for reproxalap in dry eye disease.
Benzinga Newsdesk
-
Mar 28, 2024, 12:02PM
Aldeyra Therapeutics Disclosed Clinical Development Plan For Resubmission Of New Drug Application For Reproxalap In Dry Eye Disease
Benzinga Newsdesk
-
Mar 28, 2024, 7:14AM
Tuesday, March 05, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Mar 5, 2024, 4:31PM
Thursday, January 04, 2024
Aldeyra Therapeutics Reports Advancement Of RASP Platform In Systemic And Retinal Inflammatory Diseases
Benzinga Newsdesk
-
Jan 4, 2024, 7:06AM
Thursday, December 21, 2023
On December 21, 2023, Aldeyra Therapeutics Announce That AbbVie Extended Exercise Period During Which It May Exercise Option To Enter License Agreement By Paying Non-refundable Payment Of $5M
Benzinga Newsdesk
-
Dec 21, 2023, 4:19PM
Tuesday, December 19, 2023
Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study
Vandana Singh
-
Dec 19, 2023, 1:56PM
Market-Moving News for December 19th
Benzinga Newsdesk
-
Dec 19, 2023, 8:33AM
Aldeyra Therapeutics' Phase 2 Trial Of ADX-629 For Atopic Dermatitis Shows Statistically Significant And Clinically Relevant Improvement In Investigator-assessed And Patient-reported Outcomes Across Different Physiological And Psychosocial Assessments
Benzinga Newsdesk
-
Dec 19, 2023, 7:06AM
Monday, December 18, 2023
Aldeyra Therapeutics Schedules Conference Call And Webcast On Tuesday, December 19, 2023, At 8:00 a.m. To Announce Top-Line Results From Phase 2 Clinical Trial Of ADX-629 In Patients With Atopic Dermatitis
Benzinga Newsdesk
-
Dec 18, 2023, 4:03PM
Tuesday, November 28, 2023
FDA Rejects Aldeyra Therapeutics' Dry Eye Disease Candidate, Asks For Additional Study
Vandana Singh
-
Nov 28, 2023, 11:10AM
Monday, November 27, 2023
Aldeyra Therapeutics Shares To Resume Trade At 4:35 p.m. ET
Benzinga Newsdesk
-
Nov 27, 2023, 4:13PM
Aldeyra Therapeutics Receives Complete Response Letter From FDA; Says Additional Trial Required To Demonstrate Positive Effect On The Treatment Of Ocular Symptoms In Dry Eye Disease
Benzinga Newsdesk
-
Nov 27, 2023, 4:08PM
Wednesday, November 01, 2023
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
-
Nov 1, 2023, 1:59PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Nov 1, 2023, 1:31PM
What's Going On With Aldeyra Therapeutics Stock?
Erica Kollmann
-
Nov 1, 2023, 11:52AM
Aldeyra Will Receive A Option Fee Of $1M And Upfront Payment Of $100M Less Option Fees If AbbVie Chooses To Exercise; Would Be Eligible To Receive Up To $300M In Regulatory And Commercial Milestone Payments, Inclusive Of A $100M Paymeent Upon FDA Approval
Benzinga Newsdesk
-
Nov 1, 2023, 10:54AM
Aldeyra Therapeutics shares are trading higher after the company announced that it entered into an exclusive options agreement with AbbVie.
Benzinga Newsdesk
-
Nov 1, 2023, 10:51AM
Reported Earlier, Aldeyra Therapeutics Enters Into Exclusive Option Agreement With AbbVie For License To Develop And Commercialize Reproxalap
Benzinga Newsdesk
-
Nov 1, 2023, 10:51AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Nov 1, 2023, 9:06AM
Market-Moving news for November 1st
Benzinga Newsdesk
-
Nov 1, 2023, 8:45AM
Thursday, October 19, 2023
10% Owner of Aldeyra Therapeutics Makes $4.45M Sale
Benzinga Insights
-
Oct 19, 2023, 11:03AM
Tuesday, October 17, 2023
Citigroup Maintains Buy on Aldeyra Therapeutics, Lowers Price Target to $8
Benzinga Newsdesk
-
Oct 17, 2023, 11:24AM
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Benzinga Insights
-
Oct 17, 2023, 11:00AM
Oppenheimer Downgrades Aldeyra Therapeutics to Perform
Benzinga Newsdesk
-
Oct 17, 2023, 4:18AM
Monday, October 16, 2023
Crude Oil Moves Lower; Consolidated Communications Shares Jump
Lisa Levin
-
Oct 16, 2023, 2:30PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Oct 16, 2023, 1:31PM
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
Oct 16, 2023, 1:09PM
Nasdaq Gains 1%; Charles Schwab Earnings Top Views
Lisa Levin
-
Oct 16, 2023, 12:08PM
Dow Surges Over 200 Points; Empire State Manufacturing Index Falls In October
Lisa Levin
-
Oct 16, 2023, 10:07AM
Aldeyra Therapeutics Shares Resumed Trade Then Again Halted On Circuit Breaker, This Time To The Downside, Stock Now Down -57.6%
Benzinga Newsdesk
-
Oct 16, 2023, 10:06AM
Aldeyra Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Down -55.1%
Benzinga Newsdesk
-
Oct 16, 2023, 10:00AM
Aldeyra Therapeutics Shares Resume Trade
Benzinga Newsdesk
-
Oct 16, 2023, 9:44AM
Aldeyra Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Down -66.5%
Benzinga Newsdesk
-
Oct 16, 2023, 9:42AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
Oct 16, 2023, 9:05AM
Why Aldeyra Therapeutics (ALDX) Stock Is Getting Obliterated
Henry Khederian
-
Oct 16, 2023, 8:49AM
Aldeyra Therapeutics shares are trading lower after the FDA said it identified substantive review issues in connection with the NDA for reproxalap.
Benzinga Newsdesk
-
Oct 16, 2023, 8:49AM
Aldeyra Therapeutics Says That The FDA Stated That Reproxalap For Signs And Symptoms Of Dry Eye Disease Does Not Appear To Have Data To Support The Clinical Relevance Of The Ocular Signs To Support The Dry Eye Indication - 8K
Benzinga Newsdesk
-
Oct 16, 2023, 8:11AM
Wednesday, October 04, 2023
Aldeyra Therapeutics Form13G Filing Shows Knoll Capital Management Has 6.1% Passive Stake In The Company
Benzinga Newsdesk
-
Oct 4, 2023, 3:29PM
Tuesday, September 12, 2023
President and CEO at Aldeyra Therapeutics Exercises Options Worth $1.98M
Benzinga Insights
-
Sep 12, 2023, 11:00AM
Tuesday, September 05, 2023
Manchester United, Trip.com Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin
-
Sep 5, 2023, 6:36AM
Wednesday, August 09, 2023
Expert Ratings for Aldeyra Therapeutics
Benzinga Insights
-
Aug 9, 2023, 10:00AM
Oppenheimer Reiterates Outperform on Aldeyra Therapeutics, Maintains $14 Price Target
Benzinga Newsdesk
-
Aug 9, 2023, 9:38AM
Friday, June 30, 2023
Aldeyra Therapeutics Board Member Awarded $78K Worth of Stock Options
Benzinga Insights
-
Jun 30, 2023, 11:02AM
HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $15 Price Target
Benzinga Newsdesk
-
Jun 30, 2023, 6:16AM
Thursday, June 29, 2023
Aldeyra Therapeutics Announced Topline Results From The Phase 2 Trial Of Intravitreal ADX-2191 For Retinitis Pigmentosa, Demonstrating That Relative To Baseline, The Trial Showed Statistically Significant Improvement In Retinal Function
Benzinga Newsdesk
-
Jun 29, 2023, 7:12AM
Tuesday, June 27, 2023
Aldeyra Therapeutics' Chronic Cough Potential Shows Significant Reduction In Cough Frequency Versus Placebo
Vandana Singh
-
Jun 27, 2023, 10:03AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch